Compare Apollo Global Management Ord Shs (APO) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apollo Global Management Ord Shs vs Heron Therapeutics Inc — how do they compare? Apollo Global Management Ord Shs trades at $140.17 (market cap $76.04B), while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: Apollo Global Management Ord Shs is far larger — about 1199.2× Heron Therapeutics Inc's market cap, and Apollo Global Management Ord Shs pays a 1.7% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| APO | HRTX | |
|---|---|---|
Market Cap | $76.04B | $63.41M |
Sector | Financials | Health |
52-Week High | $152.70 | $1.49 |
52-Week Low | $100.30 | $0.32 |
Enterprise Value | -$175.45B | $161.31M |
Dividend Yield | 1.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apollo Global Management (APO) trades at $127.44, down 0.43% today but maintains a bullish technical outlook with strong analyst support. The company reported mixed Q2 2026 results with an EPS miss but record $60 billion quarterly inflows, driving AUM to $1.05 trillion. Valuation metrics show a P/E of 45.35 and P/S of 2.11, with solid profitability margins and consistent dividend payments.
APO presents a compelling investment case with strong institutional backing and growth in fee-related earnings, though elevated P/E and recent earnings miss warrant caution. The consensus price target of $151.50 suggests 19% upside potential, supported by the company's leadership in private credit and AI infrastructure expansion initiatives.
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
